

AMENDMENTS TO THE CLAIMS

Claims 1-21 are pending.

Claims 14 and 17-21 are being canceled, and claims 1, 8-13, 15 and 16 are being amended.

After the amendments, claims 1-13, 15 and 16 will be pending.

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method for delivering [[a]] an oncolytic virus to a solid tumor to reduce growth of the tumor, comprising administering an effective amount of the virus to a subject bearing the tumor, wherein the virus is capable of selectively killing cells of the tumor, by
 - (1) a base administration of injecting multiple intratumor injections on the same day of a composition comprising the virus ~~into multiple sites inside the solid tumor~~, wherein the volume of the composition injected per site is between about 10% to about 100% of the volume of the tumor; and
 - (2) at least one additional administration selected from the group consisting of:
 - (a) delivering the virus by using a transdermal patch, a spray on the skin, or topical administration, wherein the tumor is a superficial tumor; and
 - (b) delivering the virus systemically.
2. (Original) The method of claim 1 wherein the virus is reovirus.
3. (Original) The method of claim 2 wherein the reovirus is a mammalian reovirus.
4. (Original) The method of claim 3 wherein the mammalian reovirus is a human reovirus.

5. (Original) The method of claim 4 wherein the human reovirus is a serotype 3 virus.
6. (Original) The method of claim 5 wherein the serotype 3 virus is a Dearing strain virus.
7. (Previously presented) The method of claim 1 wherein the virus is selected from the group consisting of modified adenovirus, modified HSV, modified vaccinia virus, modified parapoxvirus orf virus, p53-expressing viruses, the ONYX-015 virus, the Delta24 virus, vesicular stomatitis virus, the herpes simplex virus 1 mutant which is defective in hrR3, and Newcastle disease virus.
8. (Currently amended) The method of claim 1 wherein the virus is injected into at least 3 sites inside the tumor mass in the base administration.
9. (Currently amended) The method of claim 1 wherein the virus is injected into at least 5 sites inside the tumor mass in the base administration.
10. (Currently amended) The method of claim 1 wherein the virus is injected into one site per about 0.25 cubic centimeter of the tumor in the base administration.
11. (Currently amended) The method of claim 1 wherein the volume of the composition injected per site in the base administration is at least 30% of the volume of the tumor.
12. (Currently amended) The method of claim 1 wherein the volume of the composition injected per site in the base administration is at least 50% of the volume of the tumor.
13. (Currently amended) The method of claim 1 wherein the total volume of the virus composition delivered in the base administration is between about 10% to about 100% of the volume of the tumor.

Applicant : Coffey et al.
Serial No. : 09/987,687
Filed : November 15, 2001
Page : 4 of 8

Attorney's Docket No.: 16596-015001

14. (Canceled)

15. (Currently amended) The method of claim [[14]] 1 wherein the at least one additional administration is conducted before or after the base administration.

16. (Currently amended) The method of claim [[14]] 1 wherein the at least one additional administration is concurrent with the base administration.

17.-21. (Canceled)